MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leader in cancer diagnostics, today announced the launch of the Cancerguard™ test, a new multi-cancer early detection (MCED) ...

Performance evaluation of a reflex blood-based methylated ctDNA multi-cancer early detection test in individuals with obesity. A phase 1 study of intracerebroventricular (ICV) delivery of bivalent ...

You're currently following this author! Want to unfollow? Unsubscribe via the link in your email. Follow Hilary Brueck Every time Hilary publishes a story, you’ll get an alert straight to your inbox!

Exact Sciences Corp. (Nasdaq: EXAS), a leader in cancer diagnostics, today announced the launch of the Cancerguard™ test, a new multi-cancer early detection (MCED) blood test that is now available as ...

Angus is STAT’s cancer reporter. Marissa, when not working as an intern, studies extracellular vesicles in the brain in her Ph.D. research. Angus Chen covers all issues broadly related to cancer ...

MADISON, Wis., September 10, 2025 — Exact Sciences Corp. (Nasdaq: EXAS), a leader in cancer diagnostics, today announced the launch of the Cancerguard™ test, a new multi-cancer early detection (MCED) ...